Shionogi Acquires Intrabio for $2B: Rare Disease Focus | Pharma and Biotech Daily

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The pharmaceutical industry is no stranger to dynamic growth, as evidenced by Shionogi's recent acquisition of Intrabio for a staggering $2 billion. This move is more than just a financial transaction; it represents a strategic pivot towards addressing rare diseases. Through this acquisition, Shionogi gains access to Aqneursa, a drug approved for tackling two i...